Terovet: Advancing Veterinary Vaccines from Technology to Market

Terovet is a biotechnology company founded by three senior professionals with extensive experience in the veterinary vaccine industry. The team combines expertise across R&D, industrial manufacturing, quality control, and regulatory affairs, with a strong background in biologics production and vaccine development.

Throughout their careers, the founders have been directly involved in the development, scale-up, and registration of vaccine technologies across multiple international markets, including Latin America, Africa, and the Middle East.

This experience provides Terovet with a practical and execution-oriented perspective: we focus not only on developing technologies, but on ensuring they can be reliably produced and commercialized.

Today, the company operates as both an industrial partner supporting biologics manufacturing and a technology-driven organization developing proprietary veterinary vaccine solutions.

Terovet acts as a strategic partner for companies developing biologics and recombinant vaccines, supporting the transition from development to industrial manufacturing.

We specialize in the industrialization of biological processes, adapting laboratory and pilot-scale technologies to robust manufacturing environments.

Our approach is focused on execution. We work under real industrial conditions, ensuring that processes are scalable, reproducible, and aligned with regulatory expectations.

Our capabilities include:

• Industrialization and scale-up of biologics
• Technology transfer and process adaptation
• Upstream and downstream process development
• Formulation of protein-based products
• Support in regulatory alignment and manufacturing strategy

By combining technical expertise with industrial experience, we help reduce execution risk and accelerate the path to commercialization.

Terovet develops and operates proprietary platforms for the production of veterinary vaccines targeting key bacterial diseases. Our focus includes clostridial diseases, anthrax, and pasteurella, areas where reliable and scalable antigen production is critical.

At the core of our approach is a recombinant-based antigen production platform designed as an alternative to conventional technologies. This platform enables improved consistency, enhanced scalability, and better control over product quality.

Our technologies are designed not only for scientific performance, but for industrial feasibility and long-term supply reliability.

Terovet collaborates with industry partners through flexible business models designed to support development, manufacturing, and commercialization of veterinary vaccines.

We work with companies seeking to expand their portfolios, access advanced technologies, or bring products to market efficiently without developing internal manufacturing capabilities.

Our partnership models include:

Our approach allows partners to focus on market access and commercialization, while Terovet ensures product development, manufacturing, and supply.

Terovet is developing a modular biologics manufacturing facility designed to support multi-product and multi-client operations.

The platform integrates key stages of vaccine production, including upstream and downstream processing, formulation, fill and finish, and quality control.

Its modular design allows adaptation to different technologies and product types, providing flexibility for both internal developments and external projects.

The facility is designed to ensure process consistency, operational efficiency, and compliance with pharmaceutical standards, supporting reliable and scalable production.

Located in Uruguay, it benefits from a stable, export-oriented environment with strong logistics and connectivity, facilitating regional and international distribution.